ACS Publications - Curious to know more about medicinal chemistry and drug discovery? Ask ACS Medicinal Chemistry Letters' Donna Huryn anything tomorrow on r/Science: http://acspubs.co/Qm9v30eeuEa | Facebook
![Structure−Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469 | ACS Medicinal Chemistry Letters Structure−Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469 | ACS Medicinal Chemistry Letters](https://pubs.acs.org/cms/10.1021/amclct.2010.1.issue-7/asset/amclct.2010.1.issue-7.largecover.jpg)
Structure−Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469 | ACS Medicinal Chemistry Letters
![Christine and Sam's CoDEPT manuscript published in ACS Medicinal Chemistry Letters – Owen Lab – University of Utah Christine and Sam's CoDEPT manuscript published in ACS Medicinal Chemistry Letters – Owen Lab – University of Utah](https://owenlab.com/wp-content/uploads/2022/11/TOC-graphic.jpg)
Christine and Sam's CoDEPT manuscript published in ACS Medicinal Chemistry Letters – Owen Lab – University of Utah
![ACS Publications Bio & Med Chem Content on Twitter: "The first 2022 ACS Medicinal Chemistry Letters issue is out today! The cover accompanies the article by Shcherbakov et al. who report bispidine-based ACS Publications Bio & Med Chem Content on Twitter: "The first 2022 ACS Medicinal Chemistry Letters issue is out today! The cover accompanies the article by Shcherbakov et al. who report bispidine-based](https://pbs.twimg.com/media/FI--VCbXMAQrvvI.jpg)